

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **August 2021**

Commission File Number: **001-40360**

MIND MEDICINE (MINDMED) INC.

(Name of registrant)

**One World Trade Center
Suite 8500**

New York, New York 10007

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MIND MEDICINE (MINDMED) INC.
(Registrant)

Date: August 12, 2021

By: /s/ Collin Gage

Name: Collin Gage

Title: Vice President, Corporate Development

Form 6-K Exhibit Index

**Exhibit
Number**

Document Description

99.1 A copy of the registrant's Investor Presentation.



Psychedelic Inspired Medicines

August 2021

NASDAQ
MNMD

NEO
MMED

DE
MMQ



Discover. Develop. Deploy.

www.mindmed.co

Disclaimer

This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed Inc. ("MindMed" or the "Company") solely for informational purposes. None of MindMed, its affiliate or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes any representation or warranty as to the accuracy or completeness of any information contained in this Presentation. This presentation shall not constitute an offer, or a solicitation of an offer, of the sale or purchase of securities. This presentation does not constitute an offering of securities of MindMed and/or no proceeds from any representation, purchase or sale of securities shall be distributed as a proceeds of an offering of securities.

Market and Industry Data
This presentation includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. This presentation does not constitute an offering of securities of MindMed and/or no proceeds from any representation, purchase or sale of securities shall be distributed as a proceeds of an offering of securities. MindMed does not make any representation as to the accuracy of such information.

Cautionary Note on Forward-Looking Information
This presentation contains forward-looking information and forward-looking information within the meaning of applicable securities laws. Forward-looking information with respect to MindMed and its subsidiaries, statements in this presentation that are forward-looking information are based on currently available information, known facts and conditions, industry, economic and other data, and estimates, assumptions, projections, forecasts or variations involving positive variations of such words and phrases or statements that contain errors, events, results or conditions which, if they occur, would cause actual performance, achievement, activity, results or operations to be materially different from those projected in the forward-looking information. These forward-looking information are not intended to constitute an offer, or a solicitation of an offer, of the sale or purchase of securities of MindMed and/or no proceeds from any representation, purchase or sale of securities shall be distributed as a proceeds of an offering of securities.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about MindMed's ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of its investigational medicines and treatments being developed, and the ability of MindMed to raise additional capital in the future as MindMed contemplates to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, market, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievement, activity, results or operations to be materially different from those projected in the forward-looking information. These forward-looking information are not intended to constitute an offer, or a solicitation of an offer, of the sale or purchase of securities of MindMed and/or no proceeds from any representation, purchase or sale of securities shall be distributed as a proceeds of an offering of securities.

The United States federal government regulates drugs through the Controlled Substances Act. The Company works with a non-hallucinogenic synthetic derivative of the psychedelic substance (Dopamine, known as "18-AC", which is a synthetic organic molecule designed around a common, non-hallucinogenic chemical backbone. 18-AC is not a Schedule I substance in the United States and the Company does not possess 18-AC for sale to non-authorized persons. While the Company is focused on programs using psychedelic inspired compounds and clinical studies, the Company does not have any direct or indirect involvement with the manufacturing, production or distribution of any substance in the jurisdiction in which it operates. The Company is a non-psychedelic medical drug development company and does not deal with psychedelic substances except within laboratory and clinical trials settings conducted under appropriate regulatory frameworks. The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended. Investors should not rely solely on the forward-looking information. MindMed does not intend to update or revise the forward-looking information, except as may be required by applicable laws. MindMed does not intend to update or revise the forward-looking information, except as may be required by applicable laws. MindMed does not intend to update or revise the forward-looking information, except as may be required by applicable laws. MindMed does not intend to update or revise the forward-looking information, except as may be required by applicable laws.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future development, opportunities or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as a guarantee of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in US dollars unless otherwise specified. All amounts are in US dollars unless otherwise specified. All amounts are in US dollars unless otherwise specified. All amounts are in US dollars unless otherwise specified.

MindMed securities have not been approved or disapproved by the SEC or by any state, provincial or other securities regulatory authority, nor has the SEC or any state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense.



Leadership: A Combination of Drug Developers & Technologists

Robert Barrow

Chief Executive Officer



Rob is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs. Prior to joining Usona, he served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesia, rheumatology, immunology and cardiovascular disease. Rob holds a Master's degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.



Miri Halperin Wernli, PhD

Executive President & Board Director



Miri co-founded Creso Pharma, a cannabis company, and listed the company on the Australian Stock Exchange (ASX) in October 2016. Prior to founding Creso Pharma Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Astellas pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.



Dave Guebert

Chief Financial Officer



Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1980 to 1988. Since then he has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry. He currently sits as a board member and Audit Committee Chair for Legend Power Systems (TSXV: LPS), RMMI Inc. (CSE: RMMI) and Quisitive Technology Solutions, Inc. (TSXV: QUIS). From 2010 to 2017, he was board member and Audit Committee Chair of Merus Labs International Inc. (TSX: MSL; NSQ: MSL), a specialty pharmaceutical company.



Daniel Karlin, MD, MA

Chief Medical Officer



Dan previously co-founded HealthMode in 2018 and served as CEO until its acquisition by MindMed. Before that, he built and led Clinical, Informatics, and Regulatory Strategy for Pfizer's Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. Previously, he was the founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to multiple big pharma, and digital therapeutic companies. Dan is board certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is an Asst. Prof. of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.




Bradford Cross

Chief Technology Officer



Bradford previously co-founded HealthMode in 2018 and served as its CTO until its acquisition by MindMed. He is a career entrepreneur and investor with 15+ years at the intersection of AI and startups, and finance. Founded Primatic in 2012, which powered part of LinkedIn's news feed as of 2015. Machine learning for personalization and content classification. Founded DCVC in 2011, which has grown into a \$2B+ leading deep tech VC investing heavily at the intersection of computation and bio and spinning up dedicated DCVC bio fund. Founded Flightcaster in 2009, first AI Startup in YCombinator. He previously worked in distributed systems at Google 2007-2009. Brad earned degrees in Computer Science and Finance at Virginia Tech, and Mathematics at Berkeley.



Donald Gehlert, PhD

Chief Scientific Officer



Don has extensive experience in drug discovery and expertise in key functional areas of exploratory development and disease biology. During his career at Lilly, Don led or participated in teams that introduced 19 molecules into the Lilly pipeline including both small and large molecule therapies. He also participated on Phase I and Phase II clinical development teams that designed and delivered translational proof of concept studies in the areas of ADHD, obesity, AUD, depression, pain and migraine. He is a co-author on 182 publications and a co-inventor on 15 issued and pending patents.



Therapeutic Area Selection to Address Massive Unmet Needs

Tactical Capital Allocation to Advance Strategic Success

Targeting Major Psychiatric Disorders

51.5M US adults suffering from mental illness ¹

Increasing Burden over Time

21% One year prevalence of anxiety disorders in US ²

Major Driver of Overall Healthcare Costs

\$225B Annual cost of mental health in US ¹⁰

Current Treatments are Inadequate

88%

of OUD patients relapse with buprenorphine discontinuation ³

59%

of GAD patients with residual symptoms ⁴

13%

of US Population with uncontrolled pain ⁵




1. The WHO estimates indicate an estimated 51.5 million people globally suffer from mental illness. "Mental Health Statistics." World Health Organization. 2019. <https://www.who.int/news-room/fact-sheets/detail/mental-health-strengthening-our-response>




MindMed is a Mental Health Company

Rigorously Applied Drug Development Principles to a Novel Drug Class



MindMed is a Mental Health Company






Advancing Therapeutic Improvements across the Full Life Cycle



Psychedelic-Inspired Medicine Opportunity

Illustrative purposes only

Multiple Generations of Potential Drug Candidates derived from Classic Psychedelics

	CONCEPT	MINDMED APPROACH			
CLASSIC PSYCHEDELICS	<ul style="list-style-type: none"> Evidence of potential for positive clinical benefit Extensive prior human exposure Well-characterized pharmacology Potential to accelerate development program 	 DMT	 MDMA	 PSILOCYBIN	 LSD
2ND GENERATION / OPTIMIZED	<ul style="list-style-type: none"> Pharmacologically optimized molecules and dosage forms Modifications to overcome potential safety liabilities Intellectual property generation 	Prodrugs and analogues	Novel dosage forms	Novel treatment models	Novel administration methods
3RD GENERATION / NCEs	<ul style="list-style-type: none"> Structural analogues to classic psychedelics Require full development program Strongest available intellectual property 	 18-MC	Novel tryptamines	Novel phenethylamines	Non-hallucinogenic analogues

Advancing the Field with Strong IP & Strategic Competitive Moats

Protecting Innovation and Market Potential

Our Patent Positions are Extensive and Diverse

45+ patent applications filed

45+ molecules covered

30+ NCEs covered

10+

patent applications covering LSD

3+

patent applications covering 18-MC

Strategic Approach to Maximize Market Protection

- Composition of matter
- NCEs/psychedelic analogues
- Unexplored indications
- Optimized formulations with unique PK
- Proprietary methods of manufacturing
- Combination therapies
- AI and ML algorithms
- Innovative dosing protocols
- Physicochemical attributes




Science & Background

The Case for Psychedelic-Inspired Therapies

Psychedelic Inspired Medicines: A New Treatment Paradigm

A Strong Case for Psychedelic Research



LSD | Extensive Early Phase Characterization


Strong Historical Third Party Clinical Research Presents Opportunity for Accelerated Development

1000+ patients treated in clinical trials
 29 published clinical studies of LSD
 12 published clinical studies since 2008

Preliminary evidence supporting utility in:

- Anxiety
- Depression
- Alcohol use disorder

Characteristics of LSD in Human Dosing



LSD | Stands Out among the Psychedelic Drug Class Opportunities

Substantial Body of Evidence Supports Efficient Development

LSD: Overlooked & Undervalued

- Single administration with rapid and sustained action
- Robust clinical response in a wide range of conditions
- Part of psychedelic drug class with strong efficacy in preliminary studies
- No required bioactivation for activity
- Highly potent with microgram therapeutic range






Fig. 1. Whole-brain cerebral blood flow maps for the placebo and LSD conditions, plus the difference map (cluster-corrected, $P < 0.05$; $n = 15$).

LSD | Emerging Evidence in Pain & Somatic Disorders

Applications Beyond Psychiatry



Low Dose LSD Increases Pain Tolerance and Decreases Perceived Pain



Source: [14]




Kim Kuypers PhD

Associate Professor, Maastricht University
Leading researcher for repeat, sub-experiential LSD dosing

18-MC | Psychedelic-Inspired NCE: 18-MC

Non-hallucinogenic, non-cardiotoxic congener of ibogaine


18-MC Targets Substance Abuse Disorders via Different Mechanisms than Existing Therapies



18-MC | Psychedelic-Inspired NCE

Non-hallucinogenic, non-cardiotoxic congener of ibogaine

18-MC Reduces Morphine and Cocaine Self-Administration in Animal Models of Substance Use Disorder




Develop & Discover

Our Division For Concept Testing of
NCEs and Classic Psychedelics


Our Robust and Diverse Development Pipeline

Pipeline Diversification Offers Access To Full Potential Of Psychedelic Inspired Medicines



LSD Clinical Development Program

Diversified Strategy across Development Franchises



18-MC for Substance Use Disorders

Study MMED005: Phase 2 Proof-of-Concept Study of 18-MC in Opioid Withdrawal

Enrolling 96 patients at multiple centers in the US

Expected Start: Early 2022
Expected Readout: Mid 2023

Patient Population DSM-5 OUD Patients undergoing opioid withdrawal	Intervention 7-day administration Administered under observation (in-clinic)
Endpoints SOWS-Gossop (Days 1-5) Completion of withdrawal	Design Placebo controlled Dose-response Randomized, parallel-group

Collaborative Approach for Accelerating Value

Collaborations & Data Acquisition enable Rapid Path to Development With Significantly Less Risk

Exclusive UHB License Agreement



Matthias Liechti, MD, PhD
Professor & Head of Liechti Lab



More than ten years of clinical research on LSD
Dozens of completed and ongoing psychedelic trials
Exclusive rights to clinical data on LSD, psilocybin, MDMA, mescaline and DMT

18-MC Advanced by \$6.5 million NIDA Grant

\$6.5 million NIDA grant in 2013
Animal efficacy data across multiple substance use targets
Extensive preclinical safety characterization



Data Rights Acquired from UHB

Completed Phase 1

- LSD PK
- LSD fMRI
- LSD LAM
- LSD LDR
- SERT-Psilocybin
- MDMA-reboxetine interaction
- MDMA-duloxetine interaction
- MDMA-clonidine interaction
- MDMA-carvedilol interaction
- MDMA-doxazosin interaction
- MDMA-methylphenidate interaction
- MDMA-methylphenidate comparison
- MDMA-bupropion interaction
- MDMA-fear extinction
- MDMA-fMRI

Ongoing Phase 1

- LSD Psilocybin
- LSD MDMA
- LSD Ketanserin
- LSD Psilocybin and Mescaline


Ongoing Phase 2

- LSD for Anxiety Disorders
- LSD for Cluster Headaches
- LSD for Depression

Planned Phase 1

R&D Pipeline

Robust pipeline driven by collaborative arrangements



- Exclusive rights to completed and ongoing clinical study data
- Execution of Phase 1/2 studies on known and novel psychedelics
- Intended to enable efficient de-risking of new assets



- Portfolio of psychedelic-inspired NCEs
- Screening and lead optimization program ongoing
- Generates multiple patent filings



- Exclusive collaborative R&D agreement covering psychedelics
- Application of liposome technology to optimize delivery



Near-Term and Intermediate Value Drivers

DRUG CANDIDATE	INDICATION	LATE 2021	2022	MILESTONE
PSYCHIATRY FRANCHISE Project Lucy	Generalized Anxiety Disorder	●		Open IND & Launch Phase 2b study
	Anxiety disorders		●	Complete IIT in anxiety disorders
LSD — Project Flow	Adult ADHD		●	Launch Phase 2a proof-of-concept study
ADDICTION FRANCHISE 18-MC — Project Layla	Opioid Use Disorder	●		Complete Phase 1 SAD/MAD study
		●		Launch Phase 2a proof-of-concept study
PAIN FRANCHISE Project Angie	Acute Pain indication		●	Launch Phase 2 clinical program
	Chronic Pain indication		●	Launch Phase 1/2 clinical program
NEUROLOGY FRANCHISE LSD	Cluster Headache		●	Complete IIT in cluster headache
PRECLINICAL/PHASE MM-823		●		Formulation development and preclinical proof-of-concept
Mescaline		●		Launch Phase 1 IIT
DMT			●	Complete Phase 1 IIT
LSD + Ketanserin			●	Complete Phase 1 IIT



Deploy

Our Division To Enable Scalability & Accessibility of Our Drug Programs



Commercial Principles for Scalability & Accessibility

Scalable Delivery Platform to Enable Leveraging of Current Ecosystem



Digital Medicine

Use digital medicine technology to promote outcomes and engagement at all phases of the development, deployment, and clinical lifecycle

Build proprietary applications to increase patient engagement, enhance provider experience, and protect market share



Building The Psychiatric Training Infrastructure

Donating \$5 million over a 5-year period

Establish the gold standard of training programs to educate healthcare providers and psychedelic researchers



Innovative Medical Approaches

Driving adoption of our drugs through enhancement of the existing psychiatric and psychotherapeutic infrastructure

LSD neutralizer technology

Value-based reimbursement models

Digital Medicine: Multiple components of the MindMed platform

Scalable Delivery Platform to Enable Adoption Leveraging the Current Ecosystem


Early Engagement & Education

Patient education, engagement, preparation and assistance
 Deep digital diagnosis allows greater granularity to complement DSM diagnoses
 Support for treatment selection: modality dose, and timing



Treatment Session

In-session monitoring for safety, efficacy, and additional interventions
 Clinician decision support for drug and non-drug therapeutic sessions
 Predictive models linking interventions and treatment outcomes



Longitudinal Patient Engagement

Real world monitoring of trends for relapse prediction and re-treatment decisions
 Engagement in health maintenance behaviors
 AI models to inform psychotherapeutic intervention



Psychedelics Driving Progressive Care and Payment Models

Complementary Digital Medicine Approach for Improved Mental Health Outcomes

Digital Measurement enables value-based clinical models

Driving engagement through friction reducing patient technologies

Drug pricing and reimbursement driven by measured health economics & outcomes research value


High value market for providers enabled by novel reimbursement mechanisms



Digital Measures, Diagnostics & Therapeutics to Enable Commercial Viability


Building Toward Novel Care and Reimbursement Models

- 1 Build measurement, diagnostic and therapeutic models using real world data
- 2 Validate measures, diagnostics, and interventions through clinical studies run on internal app channels
- 3 Next-generation applications support full patient and provider journeys including treatments sessions and intersession monitoring
- 4 Embedded measures, diagnostics, and therapeutics to enable closed-loop value-based care and evidence for commercialization with payers




Developing Platform to Utilize all Relevant Data Types

Measurement, Diagnostics, and Therapeutics





Digital Platform Pipeline Progression Mirrors Drug Pipeline

Across Product Categories, Progression is Enabled by Technical Development and Clinical Research



Corporate Information













Share Ownership as of August 1, 2021		
Executive Team/Directors/Insiders	65,468,007	13.8%
Non-insider shares	351,330,630	74.2%
Equity Incentive Plan (Issued)	33,082,892	7.0%
Outstanding Warrants	23,387,631	4.9%
Total (Fully diluted)	473,269,160	100%

	Market Cap: \$1.2 billion July 1, 2021 (\$3.41 per share)
	Market Cap: C\$1.5 billion July 1, 2021 (C\$4.29 per share)














\$204 million
 Raised since inception including warrants

\$160 million
 Cash position as of March 31, 2021


Scientific Advisors: World Class Expert Support

 <p>Robert Malenka, MD, PhD Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University</p> 	 <p>Maurizio Fava, MD Member, Scientific Advisory Board Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)</p> 	 <p>Peter Bergethon, MD Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.</p> 	 <p>Stanley Glick, PhD Scientific Advisor for 18-MC</p> 	 <p>Matthew Johnson, PhD Professor at Johns Hopkins</p> 	
 <p>Jed Rose, PhD Professor in Psychiatry and Behavioral Sciences at Duke University</p> 	 <p>John Blacker, PhD Professor of Process Chemistry, University of Leeds</p> 	 <p>John Rotrosen, MD Professor of Psychiatry NYU Langone</p> 	 <p>Kenneth Alper, MD Clinical Associate Professor of Psychiatry and Neurology, NYU Langone</p> 	 <p>Sarah McCallum, PhD Associate Professor of Neuroscience and Experimental Therapeutics</p> 	

Board of Directors

<p>Perry Dellelce Chairman of the Board of Directors</p>  <p>Perry Dellelce is a managing partner of Wildeboer Dellelce LLP. He also serves as chair of the NEO Exchange, Canada's newest stock exchange, Board Member of Mount Logan Capital Inc. and Lendified Inc.</p> 	<p>Bruce Linton Director, Chair of Compensation, Governance and Nominating Committee</p>  <p>Bruce Linton is an activist investor with SLANG Worldwide Inc. (CSE:SLNG). Activist Investor with OG DNA Genetics Inc. Founder and Former Chairman and CEO of Canopy Growth Corporation (CGCWEED). Bruce chairs the board's Compensation, Governance and Nominating Committee.</p> 	<p>Stephen Hurst, JD Co-Founder and Director</p>  <p>Stephen Hurst has more than thirty-five years' experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health.</p> 	<p>Brigid Makes Director, Chair of Audit Committee</p>  <p>Brigid Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs. Former CFO for Nektar Therapeutics (formerly Inhal Therapeutics) B.A. in Finance and International Business from McGill University and an M.B.A. from Bentley University. Brigid chairs the board's Audit Committee.</p> 
	<p>Miri Halperin Wernli, PhD Executive President, Director</p>  <p>Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.</p> 	<p>Sarah Vinson, MD Director</p>  <p>Dr. Vinson is a Triple Board-Certified physician who specializes in adult, child & adolescent, and forensic psychiatry. She is the founder of Lorio Forensics. Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine, where she is the Program Director of the Child & Adolescent Psychiatry Fellowship, and Adjunct Faculty at Emory University School of Medicine.</p> 	

Public Perception of Psychedelics Has Changed

<p>THE WALL STREET JOURNAL</p> <p>"Psychedelics-Drug Startup Raises \$24 Million Ahead of IPO." February 27, 2020</p>	<p>Bloomberg</p> <p>"Its market capitalization of over C\$1 billion puts the company ahead of at least eight companies in Canada's benchmark S&P/TSX Composite Index, according to data compiled by Bloomberg." December 9, 2020</p>	<p>BUSINESS INSIDER</p> <p>"A startup that wants to use psychedelics to treat addiction just raised \$6.2 million from the host of Shark Tank and the architect behind the world's biggest cannabis grower" September 30, 2019</p>
<p>FASTCOMPANY</p> <p>"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?" Kevin O'Leary December 9, 2019</p>	<p>THE NEW YORKER</p> <p>"New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center." October 12, 2020</p>	<p>FORTUNE</p> <p>"Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution." February 17, 2020</p>
<p>Forbes</p> <p>"Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing" September 25, 2020</p>	<p>TOWN&COUNTRY</p> <p>"The evidence for psychedelics as medicine is far greater than that for CBD, which companies are seeking to relieve ills from Parkinson's to Crohn's." April 13, 2020</p>	 <p>"MindMed named one of 36 startups that could change the world" December 17, 2019</p>



MindMed

Sources

Mental Health By the Numbers | NAM: National Alliance on Mental Illness. (2019). NAM. <https://www.nami.org/what-is-nami/teach/2019/25%20of%20the%20U.S.%20adults%20experienced%20a%20mental%20illness%20in%20the%20last%20year>

Bandelow, Borwin, and Sophie Michéels. "Epidemiology of anxiety disorders in the 21st century." *Dialogues in clinical neuroscience* vol. 17,3 (2015): 327-35.

Weiss, R. D., Potter, J. S., Fieblin, D. A., Byrne, M., Connery, H. S., Dickinson, W., Gardin, J., Griffin, M. L., Gurevitch, M. N., Haller, D. L., Hesson, A. L., Huang, Z., Jacobs, P., Kivinski, A. S., Lindblad, R., McCance-Katz, E. F., Provost, S. E., Selzer, J., Somoza, E. C., Sonne, S. C., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Archives of general psychiatry*, 68(12), 1238-1246. <https://doi.org/10.1001/archgenpsychiatry.2011.121>

Kelly, K. M., & Mezuk, B. (2017). Predictors of remission from generalized anxiety disorder and major depressive disorder. *Journal of affective disorders*, 208, 457-474. <https://doi.org/10.1016/j.jad.2016.10.042>

Dehnamer, J., Lucas, J., Zelaysa, C., Nahin, R., Madley, S., DeBar, L., Kems, R., Von Korff, M., Porter, L., & Helmick, C. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR. Morbidity and mortality weekly report*, 67(36), 1001-1006. <https://doi.org/10.15585/mmwr.mm6736a2>

Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. *JAMA Psychiatry*. 2018;75(4):336-346. doi:10.1001/jamapsychiatry.2017.4602

2019 National Survey on Drug Use and Health, 2020

Dehnamer J, Lucas J, Zelaysa C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR Morb Mortal Wkly Rep* 2018;67:1001-1006. DOI: <http://dx.doi.org/10.15585/mmwr.mm6736a2external icon>

Wei DY, Yuan Ong JJ, Goadsby PJ. Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. *Ann Indian Acad Neurol*. 2018;21(Suppl 1):S3-S8. doi:10.4103/aiian.AIAN_349_17

Caihan-Harris RL, Leach R, Halley PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelics. *Front Hum Neurosci*. 2014;8:20. Published 2014 Feb 3. doi:10.3389/fnhum.2014.00200

Hölze, F., Vitzell, P., Ley, L., et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacol*. 46, 537-544 (2021). <https://doi.org/10.1038/s41386-020-00883-6>

Caihan-Harris RL, Muthukumarasamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. *Proc Natl Acad Sci U S A*. 2016;113(17):4853-4858. doi:10.1073/pnas.1518377113

Dunjaja GP, Iyer RN, Das G, Ahdal J, Narang P. Evidence and consensus recommendations for the pharmacological management of pain in India. *J Pain Res*. 2017;10:709-736. Published 2017 Mar 29. doi:10.2147/JPR.S128055

Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Hölze, F., Liedtke, M. E., Feilding, A., & Kuypers, K. P. (2021). A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. *Journal of psychopharmacology (Oxford, England)*, 35(4), 398-405. 13

M.I. (2020, May 6). The U.S. Mental Health Market: \$225.1 Billion In Spending In 2019: An OPEN MINDS Market Intelligence Report. OPEN MINDS. <https://openminds.com/intelligence-report/the-u-s-mental-health-market-225-1-billion-in-spending-in-2019-an-open-minds-market-intelligence-report/>